FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140453376> ?p ?o ?g. }

• W2140453376 endingPage "1969" @default.
• W2140453376 startingPage "1961" @default.
• W2140453376 abstract "Background & AimsHigh-level coffee consumption has been associated with reduced progression of pre-existing liver diseases and lower risk of hepatocellular carcinoma. However, its relationship with therapy for hepatitis C virus infection has not been evaluated.MethodsPatients (n = 885) from the lead-in phase of the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial recorded coffee intake before retreatment with peginterferon α-2a (180 μg/wk) and ribavirin (1000–1200 mg/day). We assessed patients for early virologic response (2 log10 reduction in level of hepatitis C virus RNA at week 12; n = 466), and undetectable hepatitis C virus RNA at weeks 20 (n = 320), 48 (end of treatment, n = 284), and 72 (sustained virologic response; n = 157).ResultsMedian log10 drop from baseline to week 20 was 2.0 (interquartile range [IQR], 0.6–3.9) among nondrinkers and 4.0 (IQR, 2.1–4.7) among patients that drank 3 or more cups/day of coffee (P trend <.0001). After adjustment for age, race/ethnicity, sex, alcohol, cirrhosis, ratio of aspartate aminotransferase to alanine aminotransferase, the IL28B polymorphism rs12979860, dose reduction of peginterferon, and other covariates, odds ratios for drinking 3 or more cups/day vs nondrinking were 2.0 (95% confidence interval [CI]: 1.1–3.6; P trend = .004) for early virologic response, 2.1 (95% CI: 1.1–3.9; P trend = .005) for week 20 virologic response, 2.4 (95% CI: 1.3–4.6; P trend = .001) for end of treatment, and 1.8 (95% CI: 0.8–3.9; P trend = .034) for sustained virologic response.ConclusionsHigh-level consumption of coffee (more than 3 cups per day) is an independent predictor of improved virologic response to peginterferon plus ribavirin in patients with hepatitis C. High-level coffee consumption has been associated with reduced progression of pre-existing liver diseases and lower risk of hepatocellular carcinoma. However, its relationship with therapy for hepatitis C virus infection has not been evaluated. Patients (n = 885) from the lead-in phase of the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis Trial recorded coffee intake before retreatment with peginterferon α-2a (180 μg/wk) and ribavirin (1000–1200 mg/day). We assessed patients for early virologic response (2 log10 reduction in level of hepatitis C virus RNA at week 12; n = 466), and undetectable hepatitis C virus RNA at weeks 20 (n = 320), 48 (end of treatment, n = 284), and 72 (sustained virologic response; n = 157). Median log10 drop from baseline to week 20 was 2.0 (interquartile range [IQR], 0.6–3.9) among nondrinkers and 4.0 (IQR, 2.1–4.7) among patients that drank 3 or more cups/day of coffee (P trend <.0001). After adjustment for age, race/ethnicity, sex, alcohol, cirrhosis, ratio of aspartate aminotransferase to alanine aminotransferase, the IL28B polymorphism rs12979860, dose reduction of peginterferon, and other covariates, odds ratios for drinking 3 or more cups/day vs nondrinking were 2.0 (95% confidence interval [CI]: 1.1–3.6; P trend = .004) for early virologic response, 2.1 (95% CI: 1.1–3.9; P trend = .005) for week 20 virologic response, 2.4 (95% CI: 1.3–4.6; P trend = .001) for end of treatment, and 1.8 (95% CI: 0.8–3.9; P trend = .034) for sustained virologic response. High-level consumption of coffee (more than 3 cups per day) is an independent predictor of improved virologic response to peginterferon plus ribavirin in patients with hepatitis C." @default.
• W2140453376 created "2016-06-24" @default.
• W2140453376 creator A5005769736 @default.
• W2140453376 creator A5018098715 @default.
• W2140453376 creator A5043162110 @default.
• W2140453376 creator A5067184976 @default.
• W2140453376 creator A5084125220 @default.
• W2140453376 creator A5089976309 @default.
• W2140453376 date "2011-06-01" @default.
• W2140453376 modified "2023-09-23" @default.
• W2140453376 title "Coffee Consumption Is Associated With Response to Peginterferon and Ribavirin Therapy in Patients With Chronic Hepatitis C" @default.
• W2140453376 cites W1524725311 @default.
• W2140453376 cites W1782392064 @default.
• W2140453376 cites W1978339383 @default.
• W2140453376 cites W1978783755 @default.
• W2140453376 cites W1981878298 @default.
• W2140453376 cites W1992239172 @default.
• W2140453376 cites W2003104968 @default.
• W2140453376 cites W2003805915 @default.
• W2140453376 cites W2016409892 @default.
• W2140453376 cites W2017013905 @default.
• W2140453376 cites W2024258010 @default.
• W2140453376 cites W2026614040 @default.
• W2140453376 cites W2027545702 @default.
• W2140453376 cites W2035632881 @default.
• W2140453376 cites W2041186969 @default.
• W2140453376 cites W2058538904 @default.
• W2140453376 cites W2060634146 @default.
• W2140453376 cites W2063285149 @default.
• W2140453376 cites W2063497393 @default.
• W2140453376 cites W2076731803 @default.
• W2140453376 cites W2078651468 @default.
• W2140453376 cites W2085261733 @default.
• W2140453376 cites W2086414517 @default.
• W2140453376 cites W2090439540 @default.
• W2140453376 cites W2097318836 @default.
• W2140453376 cites W2104010560 @default.
• W2140453376 cites W2116047701 @default.
• W2140453376 cites W2119802120 @default.
• W2140453376 cites W2121690051 @default.
• W2140453376 cites W2127685726 @default.
• W2140453376 cites W2130871682 @default.
• W2140453376 cites W2131221081 @default.
• W2140453376 cites W2133164076 @default.
• W2140453376 cites W2134825316 @default.
• W2140453376 cites W2137551097 @default.
• W2140453376 cites W2152320056 @default.
• W2140453376 cites W2154817439 @default.
• W2140453376 cites W2155687118 @default.
• W2140453376 cites W2156236127 @default.
• W2140453376 cites W2158442882 @default.
• W2140453376 cites W2166580125 @default.
• W2140453376 cites W2167979410 @default.
• W2140453376 cites W2168377537 @default.
• W2140453376 cites W2171255319 @default.
• W2140453376 cites W2171426453 @default.
• W2140453376 cites W4292806894 @default.
• W2140453376 doi "https://doi.org/10.1053/j.gastro.2011.02.061" @default.
• W2140453376 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3109110" @default.
• W2140453376 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21376050" @default.
• W2140453376 hasPublicationYear "2011" @default.
• W2140453376 type Work @default.
• W2140453376 sameAs 2140453376 @default.
• W2140453376 citedByCount "61" @default.
• W2140453376 countsByYear W21404533762012 @default.
• W2140453376 countsByYear W21404533762013 @default.
• W2140453376 countsByYear W21404533762014 @default.
• W2140453376 countsByYear W21404533762015 @default.
• W2140453376 countsByYear W21404533762016 @default.
• W2140453376 countsByYear W21404533762017 @default.
• W2140453376 countsByYear W21404533762018 @default.
• W2140453376 countsByYear W21404533762019 @default.
• W2140453376 countsByYear W21404533762020 @default.
• W2140453376 countsByYear W21404533762022 @default.
• W2140453376 countsByYear W21404533762023 @default.
• W2140453376 crossrefType "journal-article" @default.
• W2140453376 hasAuthorship W2140453376A5005769736 @default.
• W2140453376 hasAuthorship W2140453376A5018098715 @default.
• W2140453376 hasAuthorship W2140453376A5043162110 @default.
• W2140453376 hasAuthorship W2140453376A5067184976 @default.
• W2140453376 hasAuthorship W2140453376A5084125220 @default.
• W2140453376 hasAuthorship W2140453376A5089976309 @default.
• W2140453376 hasBestOaLocation W21404533761 @default.
• W2140453376 hasConcept C119060515 @default.
• W2140453376 hasConcept C126322002 @default.
• W2140453376 hasConcept C156957248 @default.
• W2140453376 hasConcept C203014093 @default.
• W2140453376 hasConcept C2522874641 @default.
• W2140453376 hasConcept C2776235749 @default.
• W2140453376 hasConcept C2776408679 @default.
• W2140453376 hasConcept C2776455275 @default.
• W2140453376 hasConcept C2777214474 @default.
• W2140453376 hasConcept C2778019345 @default.
• W2140453376 hasConcept C2778606649 @default.
• W2140453376 hasConcept C2780040827 @default.
• W2140453376 hasConcept C44249647 @default.
• W2140453376 hasConcept C71924100 @default.
• W2140453376 hasConcept C90924648 @default.

• next